AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38885746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 38885985 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance Use (SU)
Number of subjects: 17585
Study 38885985 — intervention group
Group type: EXPERIMENTAL
Intervention: Hazardous Drinking (HD)
Number of subjects: 17585
Study 38885985 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent Substance Use and Hazardous Drinking (SU and HD)
Number of subjects: 17585
Study 38885985 — intervention group
Group type: COMPARATOR
Intervention: Control group (not engaging in HD or SU)
Number of subjects: 17585
Study 38885990 — intervention group
Group type: EXPERIMENTAL
Intervention: qER software by Qure.ai
Number of subjects: 0
Study 38885990 — intervention group
Group type: COMPARATOR
Intervention: Standard care (pre-implementation phase)
Number of subjects: 0
Study 38885990 — intervention group
Group type: EXPERIMENTAL
Intervention: qER solution with prioritised flag in the radiology information system (post-implementation phase)
Number of subjects: 0
Study 38885991 — intervention group
Group type: EXPERIMENTAL
Intervention: Q3 (PNI ≥ 59.80)
Number of subjects: 14883
Study 38885991 — intervention group
Group type: COMPARATOR
Intervention: Q2 (51.35 ≤ PNI < 59.80)
Number of subjects: 14883
Study 38885991 — intervention group
Group type: EXPERIMENTAL
Intervention: Q1 (PNI <51.35)
Number of subjects: 14883
Study 38886011 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral episiotomy
Number of subjects: 717
Study 38886011 — intervention group
Group type: COMPARATOR
Intervention: No episiotomy
Number of subjects: 717
Study 38886011 — intervention group
Group type: COMPARATOR
Intervention: No significant differences
Number of subjects: 717
Study 38886116 — intervention group
Group type: EXPERIMENTAL
Intervention: AdAPT-001
Number of subjects: 0
Study 38886159 — intervention group
Group type: EXPERIMENTAL
Intervention: Entinostat 5 mg weekly
Number of subjects: 5
Study 38886235 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided preemptive retrolaminar block (RLB)
Number of subjects: 60
Study 38886235 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 60
Study 38886304 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-minute walk test
Number of subjects: 22
Study 38886304 — intervention group
Group type: COMPARATOR
Intervention: Cardiopulmonary exercise test (VO2)
Number of subjects: 22
Study 38886347 — intervention group
Group type: EXPERIMENTAL
Intervention: FS-1502 (anti-HER2 ADC) at recommended phase 2 dose (RP2D) of 2.3 mg/kg once every 3 weeks.
Number of subjects: 150
Study 38886347 — intervention group
Group type: EXPERIMENTAL
Intervention: FS-1502 (anti-HER2 ADC) at doses of 3.0 and 3.5 mg/kg.
Number of subjects: 150
Study 38886347 — intervention group
Group type: EXPERIMENTAL
Intervention: FS-1502 (anti-HER2 ADC) at RP2D of 2.3 mg/kg.
Number of subjects: 150
Study 38886516 — intervention group
Group type: EXPERIMENTAL
Intervention: Talazoparib
Number of subjects: 2
Study 38886516 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 2
Study 38886623 — intervention group
Group type: EXPERIMENTAL
Intervention: Duvelisib plus romidepsin
Number of subjects: 98
Study 38886623 — intervention group
Group type: COMPARATOR
Intervention: Duvelisib plus bortezomib
Number of subjects: 98
Study 38886719 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative strategies for quitting vaping
Number of subjects: 11
Study 38886719 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to quitting vaping
Number of subjects: 11
Study 38886719 — intervention group
Group type: EXPERIMENTAL
Intervention: Quit strategies for vaping
Number of subjects: 11
Study 38886774 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance-dependent functional connectivity density (FCD) in left subcortical stroke patients (LSS)
Number of subjects: 86
Study 38886774 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance-dependent functional connectivity density (FCD) in right subcortical stroke patients (RSS)
Number of subjects: 86
Study 38886774 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 86
Study 38886814 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week group-based telemedicine self-management intervention
Number of subjects: 50
Study 38886814 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 50
Study 38886836 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab-based chemotherapy
Number of subjects: 79
Study 38886836 — intervention group
Group type: EXPERIMENTAL
Intervention: TTLD ratio > 0.6 at baseline and first restaging
Number of subjects: 79
Study 38886836 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline TTLD ratio > 0.6
Number of subjects: 79
Study 38886836 — intervention group
Group type: EXPERIMENTAL
Intervention: TTLD absolute values at baseline and first restaging
Number of subjects: 79
Study 38886974 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual 'I-for-me' PA planning intervention
Number of subjects: 247
Study 38886974 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative 'we-for-us' PA planning intervention
Number of subjects: 247
Study 38886974 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyadic 'we-for-me' PA planning intervention
Number of subjects: 247
Study 38886974 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 247
Study 38887480 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV self-testing
Number of subjects: 40
Study 38887493 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut microbiota and metabolites analysis in SA-AKI patients
Number of subjects: 4
Study 38887493 — intervention group
Group type: COMPARATOR
Intervention: Gut microbiota and metabolites analysis in non-AKI patients
Number of subjects: 4
Study 38887493 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparative analysis of gut microbiota and metabolites
Number of subjects: 4
Study 38887884 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective intracoronary hypothermia during primary PCI
Number of subjects: 200
Study 38887884 — intervention group
Group type: COMPARATOR
Intervention: Primary PCI alone
Number of subjects: 200
Study 38887951 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiology-guided complete revascularization
Number of subjects: 1445
Study 38887951 — intervention group
Group type: COMPARATOR
Intervention: Culprit-only revascularization
Number of subjects: 1445
Study 38887953 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messages encouraging low-level physical activity (delivered via smartwatch)
Number of subjects: 108
Study 38887953 — intervention group
Group type: COMPARATOR
Intervention: No text message (control group)
Number of subjects: 108
Study 38888179 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-2 + CCK (10 pmol × kg-1 × min-1 + 0.4 pmol × kg-1 × min-1)
Number of subjects: 15
Study 38888179 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-2 + placebo
Number of subjects: 15
Study 38888179 — intervention group
Group type: COMPARATOR
Intervention: CCK + placebo
Number of subjects: 15
Study 38888179 — intervention group
Group type: COMPARATOR
Intervention: placebo + placebo
Number of subjects: 15
Study 38888288 — intervention group
Group type: EXPERIMENTAL
Intervention: Voretigene neparvovec-rzyl
Number of subjects: 4
Study 38888288 — intervention group
Group type: COMPARATOR
Intervention: rAAV2-CB-hRPE65
Number of subjects: 4
Study 38888480 — intervention group
Group type: EXPERIMENTAL
Intervention: FFDM plus UST
Number of subjects: 140
Study 38888480 — intervention group
Group type: COMPARATOR
Intervention: FFDM alone
Number of subjects: 140
Study 38888484 — intervention group
Group type: EXPERIMENTAL
Intervention: Affibody-based tracer (specific details not provided)
Number of subjects: 0
Study 38888484 — intervention group
Group type: COMPARATOR
Intervention: Nonspecific radiotracers (specific details not provided)
Number of subjects: 0
Study 38888538 — intervention group
Group type: EXPERIMENTAL
Intervention: PortionSize
Number of subjects: 14
Study 38888616 — intervention group
Group type: EXPERIMENTAL
Intervention: zanubrutinib (160 mg twice-daily)
Number of subjects: 90
Study 38888616 — intervention group
Group type: COMPARATOR
Intervention: ibrutinib (420 mg once-daily)
Number of subjects: 90
Study 38888616 — intervention group
Group type: EXPERIMENTAL
Intervention: zanubrutinib
Number of subjects: 90
Study 38888616 — intervention group
Group type: COMPARATOR
Intervention: ibrutinib
Number of subjects: 90
Study 38888681 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg
Number of subjects: 3802
Study 38888681 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib 100 mg
Number of subjects: 3802
Study 38888681 — intervention group
Group type: COMPARATOR
Intervention: Abrocitinib (variable-dose cohort)
Number of subjects: 3802
Study 38888681 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib
Number of subjects: 3802
Study 38888700 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco heating system (THS) smokers
Number of subjects: 0
Study 38888700 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smokers
Number of subjects: 0
Study 38888700 — intervention group
Group type: COMPARATOR
Intervention: Non-smokers
Number of subjects: 0
Study 38888846 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular lidocaine
Number of subjects: 0
Study 38888846 — intervention group
Group type: COMPARATOR
Intervention: Control (0.9% saline)
Number of subjects: 0
Study 38888905 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonphysician community health care practitioner-led intensive blood pressure intervention
Number of subjects: 22386
Study 38888905 — intervention group
Group type: COMPARATOR
Intervention: Usual-care group
Number of subjects: 22386
Study 38888909 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel highly sensitive immunoassay for long cTnT using upconversion luminescence
Number of subjects: 67
Study 38888909 — intervention group
Group type: COMPARATOR
Intervention: Previously developed TRF long cTnT assay
Number of subjects: 67
Study 38888909 — intervention group
Group type: COMPARATOR
Intervention: Commercial high-sensitivity cTnT assay
Number of subjects: 67
Study 38888952 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile health app (Malo) for screening neurodevelopmental disorders (NDDs) and preventing postnatal depression (PND)
Number of subjects: 55618
Study 38888952 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile health app (Malo) for PND detection
Number of subjects: 55618
Study 38888952 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile health app (Malo) user satisfaction
Number of subjects: 55618
Study 38888958 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week MBCT intervention plus treatment as usual (MBCT + TAU)
Number of subjects: 128
Study 38888958 — intervention group
Group type: COMPARATOR
Intervention: 8-week waitlist control group
Number of subjects: 128
Study 38889140 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP + standard physiotherapy
Number of subjects: 63
Study 38889140 — intervention group
Group type: EXPERIMENTAL
Intervention: BiPAP + standard physiotherapy
Number of subjects: 63
Study 38889140 — intervention group
Group type: COMPARATOR
Intervention: standard physiotherapy
Number of subjects: 63
Study 38889160 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient treatment for psychotic disorders
Number of subjects: 66
Study 38889213 — intervention group
Group type: EXPERIMENTAL
Intervention: CMR-QP (Cardiac Magnetic Resonance Quantitative Perfusion) interpretation by an expert reader
Number of subjects: 359
Study 38889213 — intervention group
Group type: COMPARATOR
Intervention: Visual analysis alone
Number of subjects: 359
Study 38889213 — intervention group
Group type: EXPERIMENTAL
Intervention: CMR-QP
Number of subjects: 359
Study 38889247 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1345 50-µg vaccine
Number of subjects: 17793
Study 38889247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17793
Study 38889372 — intervention group
Group type: EXPERIMENTAL
Intervention: European Organisation for Research and Treatment of Cancer QoL Core 30 questionnaire (QLQ-C30) summary score at diagnosis and 1 and 2 years postdiagnosis.
Number of subjects: 5915
Study 38889372 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression-based slope index of inequality (SII) for QLQ-C30 summary score.
Number of subjects: 5915
Study 38889373 — intervention group
Group type: EXPERIMENTAL
Intervention: Amcenestrant 200 mg once daily + palbociclib 125 mg once daily (21 days on/7 days off)
Number of subjects: 1068
Study 38889373 — intervention group
Group type: COMPARATOR
Intervention: Letrozole 2.5 mg once daily + palbociclib 125 mg once daily (21 days on/7 days off)
Number of subjects: 1068
Study 38889377 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 1197
Study 38889377 — intervention group
Group type: COMPARATOR
Intervention: Standard adjuvant chemotherapy
Number of subjects: 1197
Study 38889431 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical sildenafil cream (3.6%)
Number of subjects: 200
Study 38889431 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 200
Study 38889737 — intervention group
Group type: EXPERIMENTAL
Intervention: Epcoritamab monotherapy
Number of subjects: 128
Study 38889735 — intervention group
Group type: EXPERIMENTAL
Intervention: D-VTd (bortezomib, thalidomide, and dexamethasone with daratumumab)
Number of subjects: 1085
Study 38889735 — intervention group
Group type: EXPERIMENTAL
Intervention: D-VTd with daratumumab maintenance
Number of subjects: 1085
Study 38889735 — intervention group
Group type: EXPERIMENTAL
Intervention: VTd with daratumumab maintenance
Number of subjects: 1085
Study 38889735 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 1085
Study 38889946 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow cytometric analysis of peripheral blood neutrophil myeloperoxidase expression
Number of subjects: 400
Study 38889946 — intervention group
Group type: COMPARATOR
Intervention: Reference standard (cytomorphological evaluation of bone marrow)
Number of subjects: 400
Study 38890129 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobalt-chromium thin-strut polymer-free biolimus-coated stent (CoCr-BCS)
Number of subjects: 57
Study 38890164 — intervention group
Group type: EXPERIMENTAL
Intervention: HFNO and non-invasive mechanical ventilation
Number of subjects: 107
Study 38890164 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary co-infection
Number of subjects: 107
Study 38890164 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive mechanical ventilation
Number of subjects: 107
Study 38890164 — intervention group
Group type: COMPARATOR
Intervention: Standard oxygen therapy
Number of subjects: 107
Study 38890164 — intervention group
Group type: COMPARATOR
Intervention: Overall management
Number of subjects: 107
Study 38890182 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-selected music
Number of subjects: 321
Study 38890182 — intervention group
Group type: COMPARATOR
Intervention: Silence
Number of subjects: 321
Study 38890186 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level light/laser therapy (LLLT)
Number of subjects: 0
Study 38890186 — intervention group
Group type: COMPARATOR
Intervention: Fractional carbon dioxide laser (FCO2)
Number of subjects: 0
Study 38890239 — intervention group
Group type: EXPERIMENTAL
Intervention: TEAS plus remimazolam (group E)
Number of subjects: 108
Study 38890239 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl plus remimazolam (group C)
Number of subjects: 108
Study 38890239 — intervention group
Group type: COMPARATOR
Intervention: Placebo-TEAS plus remimazolam (group P)
Number of subjects: 108
Study 38890271 — intervention group
Group type: EXPERIMENTAL
Intervention: Pf-infected mosquitoes exposure
Number of subjects: 8
Study 38890302 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice fortified with vitamins and minerals (specific types not detailed) for six months
Number of subjects: 380
Study 38890302 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 380
Study 38890563 — intervention group
Group type: EXPERIMENTAL
Intervention: MaxiPost (0.05 mg/min)
Number of subjects: 21
Study 38890563 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isotonic saline)
Number of subjects: 21
Study 38890627 — intervention group
Group type: EXPERIMENTAL
Intervention: Nano Silver Fluoride (NSF)
Number of subjects: 360
Study 38890627 — intervention group
Group type: COMPARATOR
Intervention: Silver Diamine Fluoride (SDF)
Number of subjects: 360
Study 38890641 — intervention group
Group type: EXPERIMENTAL
Intervention: eliapixant 25 mg BID
Number of subjects: 215
Study 38890641 — intervention group
Group type: EXPERIMENTAL
Intervention: eliapixant 75 mg BID
Number of subjects: 215
Study 38890641 — intervention group
Group type: EXPERIMENTAL
Intervention: eliapixant 150 mg BID
Number of subjects: 215
Study 38890641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study 38890641 — intervention group
Group type: EXPERIMENTAL
Intervention: elagolix 150 mg once daily
Number of subjects: 215
Study 38890655 — intervention group
Group type: EXPERIMENTAL
Intervention: IV-DXN (4 mg/ml DXN)
Number of subjects: 45
Study 38890655 — intervention group
Group type: EXPERIMENTAL
Intervention: PN-DXN (1 ml of 4 mg/ml DXN)
Number of subjects: 45
Study 38890655 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 45
Study 38890709 — intervention group
Group type: EXPERIMENTAL
Intervention: Online self-help 14-day Acceptance and Commitment Therapy (ACT) training
Number of subjects: 192
Study 38890709 — intervention group
Group type: COMPARATOR
Intervention: Minimally enhanced usual care (mEUC) control group
Number of subjects: 192
Study 38890744 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupported pharmacy-delivered PrEP services
Number of subjects: 1900
Study 38890744 — intervention group
Group type: COMPARATOR
Intervention: Supported pharmacy-delivered PrEP services with nurse navigator
Number of subjects: 1900
Study 38890744 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 1900
Study 38890744 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploratory outcomes
Number of subjects: 1900
Study 38891149 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Therapy (MT)
Number of subjects: 60
Study 38891149 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronized Telerehabilitation (TR)
Number of subjects: 60
Study 38891149 — intervention group
Group type: COMPARATOR
Intervention: Home Exercise (HE)
Number of subjects: 60
Study 38891190 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Club Denmark (FCD) intervention
Number of subjects: 510
Study 38891190 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 510
Study 38891799 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic therapy for 12 weeks
Number of subjects: 15
Study 38891799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 38892218 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma trimethylamine-N-oxide (TMAO) levels in LTRs
Number of subjects: 367
Study 38892218 — intervention group
Group type: COMPARATOR
Intervention: Plasma trimethylamine-N-oxide (TMAO) levels in the general population (PREVEND cohort)
Number of subjects: 367
Study 38892507 — intervention group
Group type: EXPERIMENTAL
Intervention: Micellar Vitamin D
Number of subjects: 0
Study 38892507 — intervention group
Group type: COMPARATOR
Intervention: Standard Vitamin D
Number of subjects: 0
Study 38892525 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean low-FODMAP diet (MED-LFD)
Number of subjects: 0
Study 38892525 — intervention group
Group type: COMPARATOR
Intervention: NICE recommendations diet
Number of subjects: 0
Study 38892738 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater Occipital Nerve Blockade
Number of subjects: 0
Study 38892738 — intervention group
Group type: EXPERIMENTAL
Intervention: Sphenopalatine Ganglion Blockade
Number of subjects: 0
Study 38892841 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized seating system with hips significantly abducted for at least five hours/day for two years
Number of subjects: 0
Study 38892841 — intervention group
Group type: COMPARATOR
Intervention: Adaptive seating system with pelvis and lower limbs aligned but hips less abducted
Number of subjects: 0
Study 38892841 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 38892879 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 38893184 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT) boost, single dose of 20 Gy, administered immediately after tumor resection.
Number of subjects: 1133
Study 38895199 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fluoropyrimidine treatment
Number of subjects: 0
Study 38895600 — intervention group
Group type: EXPERIMENTAL
Intervention: SPAIRE approach
Number of subjects: 244
Study 38895600 — intervention group
Group type: COMPARATOR
Intervention: Lateral approach
Number of subjects: 244
Study 38895640 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration-controlled transient elastography (VCTE) with CAP of 281 dB/m
Number of subjects: 82
Study 38895640 — intervention group
Group type: COMPARATOR
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 82
Study 38895699 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal CT (NCCT, CTA, CTP)
Number of subjects: 3000
Study 38895699 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinded results from imaging scans by radiologists and AI technology
Number of subjects: 3000
Study 38895699 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic indicators and costs analysis
Number of subjects: 3000
Study 38895897 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI) - brief (4 weeks)
Number of subjects: 60
Study 38895897 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI) - standard (8 weeks)
Number of subjects: 60
Study 38895897 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI) - extended (12 weeks)
Number of subjects: 60
Study 38896056 — intervention group
Group type: EXPERIMENTAL
Intervention: NPM1 testing
Number of subjects: 7285
Study 38896056 — intervention group
Group type: EXPERIMENTAL
Intervention: FLT3-ITD testing
Number of subjects: 7285
Study 38896056 — intervention group
Group type: EXPERIMENTAL
Intervention: NGS testing
Number of subjects: 7285
Study 38896056 — intervention group
Group type: EXPERIMENTAL
Intervention: Karyotype studies
Number of subjects: 7285